Trial reportThe pharmacogenomics journal2014
Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS).
Trial report in The pharmacogenomics journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Lithium-responsive genes and gene networks in bipolar disorder patient-derived lymphoblastoid cell lines.The pharmacogenomics journal · 2016Trial
- Ab Initio Investigation of the Electronic Structure and Spectroscopy of LiTe and LiTeACS omega · 2026Article
- Circadian clock genes and cell survival in bipolar disorder: Insights into lithium responsiveness and molecular mechanisms in patient-derived neural progenitor cells and mouse neurons.The FEBS journal · 2025Article
- Article
- New Advances in the Pharmacology and Toxicology of Lithium: A Neurobiologically Oriented Overview.Pharmacological reviews · 2024Review
- Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study.Discover mental health · 2024Article
- Contributions of circadian clock genes to cell survival in fibroblast models of lithium-responsive bipolar disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2023Article
- RNA Biomarkers in Bipolar Disorder and Response to Mood Stabilizers.International journal of molecular sciences · 2023Review
- Divergent Directionality of Immune Cell-Specific Protein Expression between Bipolar Lithium Responders and Non-Responders Revealed by Enhanced Flow Cytometry.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- A gene co-expression module implicating the mitochondrial electron transport chain is associated with long-term response to lithium treatment in bipolar affective disorder.Translational psychiatry · 2018Article
- The observed alteration in BCL2 expression following lithium treatment is influenced by the choice of normalization method.Scientific reports · 2018Article
- Predicting lithium treatment response in bipolar patients using gender-specific gene expression biomarkers and machine learning.F1000Research · 2018Article
- Effects of Lithium Monotherapy for Bipolar Disorder on Gene Expression in Peripheral Lymphocytes.Molecular neuropsychiatry · 2016Article
- Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.CNS drugs · 2016Review
- Dysplasticity, metaplasticity, and schizophrenia: Implications for risk, illness, and novel interventions.Development and psychopathology · 2015Review
- Olfactory neurons obtained through nasal biopsy combined with laser-capture microdissection: a potential approach to study treatment response in mental disorders.Journal of visualized experiments : JoVE · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
This study was designed to identify genes whose expression in peripheral blood may serve as early markers for treatment response to lithium (Li) in patients with bipolar disorder. Although changes in peripheral blood gene-expression may not relate directly to mood symptoms, differences in treatment response at the biochemical level may underlie some of the heterogeneity in clinical response to Li. Subjects were randomized to treatment with (n=28) or without (n=32) Li. Peripheral blood gene-expression was measured before and 1 month after treatment initiation, and treatment response was assessed after 6 months. In subjects treated with Li, 62 genes were differentially regulated in treatment responders and non-responders. Of these, BCL2L1 showed the greatest difference between Li responders and non-responders. These changes were specific to Li responders (n=9), and were not seen in Li non-responders or patients treated without Li, suggesting that they may have specific roles in treatment response to Li.
Indexed as
Identifiers
23670706What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.